Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints

Multiple Sclerosis

Volumn 22, Issue 3, 2016, Pages 329-339

  Jeong, In Hye ^a   Park, Boram ^b   Kim, Su Hyun ^a   Hyun, Jae Won ^a   Joo, Jungnam ^b   Kim, Ho Jin ^a  

^a National Cancer Center   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

azathioprine; mycophenolate mofetil; Neuromyelitis optica; rituximab; treatment

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLATE MOFETIL; PREDNISOLONE; RITUXIMAB;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; AGED; ARTICLE; AVASCULAR NECROSIS; COMPARATIVE STUDY; DISEASE DURATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; PANCYTOPENIA; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; FOLLOW UP; MIDDLE AGED; NEUROMYELITIS OPTICA; RECURRENT DISEASE; YOUNG ADULT; CONTROLLED STUDY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; HYPERTRANSAMINASEMIA; RECURRENCE RISK;

ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84986552388     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515587752     Document Type: Article

References (20)

1. Kim W, Kim SH, Kim HJ,. New insights into neuromyelitis optica. J Clinical Neurol 2011; 7: 115-127.
2. Costanzi C, Matiello M, Lucchinetti CF, et al. Azathioprine: Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 2011; 77: 659-666.
3. Bichuetti DB, Lobato de Oliveira EM, Oliveira DM, et al. Neuromyelitis optica treatment: analysis of 36 patients. Arch Neurol 2010; 67: 1131-1136.
4. Elsone L, Kitley J, Luppe S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK. Mult Scler 2014; 20: 1533-1540.
5. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009; 66: 1128-1133.
6. Huh SY, Kim SH, Hyun JW, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014; 71: 1372-1378.
7. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
8. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
9. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011; 76: 1310-1315.
10. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17: 1225-1230.
11. Ip VH, Lau AY, Au LW, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 2013; 324: 38-39.
12. Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013; 70: 1110-1117.
13. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 2013; 81: 710-713.
14. Kim SH, Kim W, Park MS, et al. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 2011; 68: 473-479.
15. Cabre P, Olindo S, Marignier R, et al. Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 2013; 84: 511-516.
16. Kitley J, Elsone L, George J, et al. Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 2013; 84: 918-921.
17. Ramanathan RS, Malhotra K, Scott T,. Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol 2014; 14: 51.
18. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
19. Wingerchuk DM, Lennon VA, Lucchinetti CF, et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
20. Mealy MA, Wingerchuk DM, Palace J, et al. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy. JAMA Neurol 2014; 71: 324-330.